Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

Roche Holdings AG's RHHBY Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) met its primary and secondary endpoints. The data showed oral fenebrutinib ...

Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trials ...

Evobrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduced gadolinium-enhancing lesions in patients with multiple sclerosis. Patients with relapsing multiple sclerosis (MS) who received 75 ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said its oral drug fenebrutinib met the main and secondary goals of a phase 2 trial by reducing brain lesions in adults with relapsing forms of multiple sclerosis ...

Even with disease-modifying therapies, patients who have chronically active inflammatory MS lesions can expect an aggressive disease course and poor outcomes. A new study shows that patients with ≥4 ...

Patients with multiple sclerosis who received natalizumab therapy had lower relapse rates and reduced inflammation. Natalizumab (NTZ) was found to be an effective treatment for reducing inflammation ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase II FENopta study evaluating ...